Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK102 in Heterozygous Familial Hypercholesterolemia
NCT04173793Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2019
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Akeso, Inc.. Started Nov 2019; status: completed.
02
Drugs
ebronucimab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT04173793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173793.